drugset
drugset / Trial / NCT04464525

Omecamtiv Mecarbil Post-trial Access Study

NCT04464525 ↗

Phase 3 Withdrawn Cytokinetics
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to provide access to omecamtiv mecarbil for participants who have completed GALACTIC-HF 20110203.

Timeline

Start
2020-12-18
Primary completion
2026-11-27
Completion
2026-11-27

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Background Omecamtiv Mecarbil Small molecule — Oral

Indications

congestive heart failure